Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-50,000
Closed -$5.22M 160
2020
Q4
$5.22M Sell
50,000
-250,000
-83% -$25.3M 0.11% 105
2020
Q3
$21.2M Sell
300,000
-200,000
-40% -$13.9M 0.52% 43
2020
Q2
$32.1M Sell
500,000
-2,500,000
-83% -$137M 0.9% 31
2020
Q1
$89.8M Sell
3,000,000
-1,606,298
-35% -$37M 3.8% 6
2019
Q4
$90.1M Hold
4,606,298
3.48% 7
2019
Q3
$73.3M Hold
4,606,298
2.94% 8
2019
Q2
$67.4M Sell
4,606,298
-400,000
-8% -$8.59M 2.73% 9
2019
Q1
$102M Sell
5,006,298
-250,000
-5% -$4.64M 4.16% 3
2018
Q4
$80.3M Buy
+5,256,298
New +$86.4M 2.97% 6

Other funds holding MRNA

Artal Group's MRNA Position: Q1 2021 in Review

Artal Group sold out of Moderna (MRNA) in Q1 2021, closing a stake of 50,000 shares — an estimated $5.22M sold.

Artal Group first reported a position in MRNA in Q4 2018 and held it in 9 quarters. The position peaked at $102M in Q1 2019. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • Artal Group reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
  • Artal Group sold 50,000 Moderna shares in Q1 2021, an estimated $5.22M.
  • Artal Group first reported a position in Moderna in Q4 2018 and held it in 9 quarters.
  • Artal Group's Moderna position peaked at $102M in Q1 2019.
  • 776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.